At the end of January 2017, the US Department of Transportation proposed new rules in the Federal Register to modify its current DOT drug testing program to add hydrocodone, oxymorphone, oxycodone, and hydromorphone to its panel. These synthetic opioids would be included in the present “opiates” category and change the category name to “opioids.” In this same proposal, they also include adding methylenedioxyamphetamine (MDA) as an initial test analyte and remove methylenedioxymethamphetamine, (MDEA) as a confirmatory test analyte.
These revisions were created to fit more seamlessly with the new Mandatory Guidelines established by the US Department of Health and Human Services (DHHS) regarding federal, urine drug testing, which was also issued on January 23, 2017. These revisions have been considered after reviewing current drug abuse trends.
DOT is also proposing:
The effective date set for the DHHS compliances is October 1, 2017, with its final revisions. DOT will continue to accept comments to this notice of proposed rulemaking until March 24, 2017.
Keeping your employees and others safe from the harms caused by opioids and other drugs is what’s most important to the team at Occupational Drug Testing. We service both DOT and non-DOT businesses for their drug testing needs and do it all from the convenience of our mobile testing vehicles.
With more questions about how we can help your business, call us today at (800) 211-4469.